Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the italian atazanavir expanded access program and master cohorts

Infection

Volumn 37, Issue 3, 2009, Pages 244-249

  Torti, C ^a   Lapadula, G ^a   Antinori, A ^b   Quirino, T ^c   Maserati, R ^d   Castelnuovo, F ^e   Maggiolo, F ^f   De Luca, A ^g   Paraninfo, G ^e   Antonucci, F ^b   Migliorino, G ^c   Lazzarin, A ^h   Di Perri, G ⁱ   Rizzardini, G ^j   Esposito, R ^k   Carosi, G ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c OSPEDALE DI CIRCOLO   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e SPEDALI CIVILI   (Italy)

^f OSPEDALI RIUNITI   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j UNIVERSITY OF MILAN   (Italy)

^k UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ATAZANAVIR; BILIRUBIN; RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OLIGOPEPTIDE; PYRIDINE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; FEMALE; HEALTH PROGRAM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; ANALYSIS OF VARIANCE; BLOOD; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; DRUG EFFECT; ENZYMOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY;

ADULT; ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; HYPERBILIRUBINEMIA; LIVER; MALE; MULTIVARIATE ANALYSIS; OLIGOPEPTIDES; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PYRIDINES; RISK FACTORS; RITONAVIR; SEVERITY OF ILLNESS INDEX;

EID: 67650245743     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-8010-6     Document Type: Article

References (16)

1. M. Johnson B. Grinsztejn C. Rodriguez 2005 Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures AIDS 19 685 694
2. Molina JM, Andrade-Villanueva J, Echevarria J et al.: Efficacy and safety of once-daily atazanavir/ritonavir compared to twicedaily lopinavir/ritonavir, each in combination with tenofovir and emtricitabinein in ARV-naive HIV-1-infected subjects: The CASTLE study, 48-week results (abstract no. 37). Boston, MA: 15th Conference on Retroviruses and Opportunistic Infections, 2008.
3. I. Sanne P. Piliero K. Squires A. Thiry S. Schnittman 2003 Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects J Acquir Immune Defic Syndr 32 18 29
4. K. Squires A. Lazzarin J.M. Gatell 2004 Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV J Acquir Immune Defic Syndr 36 1011 1019
5. Ward D, Curtin J, Richardson J et al: Hyperbilirubinemia among Patients in the HIV Outpatient Study (HOPS) receiving atazanavir (abstract TuPe2 1B02). Rio de Janeiro: 3rd International AIDS Conference on HIV Pathogenesis and Treatment, 2005.
6. R. Wood P. Phanuphak P. Cahn 2004 Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir J Acquir Immune Defic Syndr 36 684 692
7. Anonymous: 1993 Revised classification system for HIV infectionexpanded surveillance case definition for AIDS among adolescentsadults. 1992 MMWR Recomm Rep 41 1 19
8. H. Al-Mohri C. Cooper T. Murphy M.B. Klein 2005 Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients HIV Med 6 375 378
9. J. Gatell D. Salmon-Ceron A. Lazzarin 2007 Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results Clin Infect Dis 44 1484 1492
10. D.V. Havlir S.D. O'Marro 2004 Atazanavir: new option for treatment of HIV infection Clin Infect Dis 38 1599 1604
11. R.L. Murphy I. Sanne P. Cahn 2003 Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results AIDS 17 2603 2614
12. S. Colombo T. Buclin M. Cavassini 2006 Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection Antimicrob Agents Chemother 50 3801 3808
13. E. Dailly O. Tribut P. Tattevin 2006 Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients Eur J Clin Pharmacol 62 523 526
14. D.E. Smith S. Jeganathan J. Ray 2006 Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations HIV Clin Trials 7 34 38
15. M. Rotger P. Taffe G. Bleiber 2005 Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia J Infect Dis 192 1381 1386
16. M. Johnson B. Grinsztejn C. Rodriguez 2006 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures AIDS 20 711 718